\n
\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on
.<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe> We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nIxekizumab plus tirzepatide yielded significant improvement over ixekizumab alone in ACR50 response in patients with PsA and obesity.<\/li>\n No new safety signals were observed.<\/li>\n<\/ul>\nTreatment with ixekizumab plus tirzepatide achieves greater disease control, physical function and weight loss vs. monotherapy in patients with psoriatic arthritis and obesity, according to data published in Arthritis Care & Research<\/i>. <\/p>\n
\u201cOverweight or obesity is disproportionately prevalent in PsA compared with the general population, with estimates ranging from 72% to 82%,\u201d Joseph F. Merola, MD,<\/b> of the University of Texas Southwestern Medical Center and O\u2019Donnell School of Public Health, and colleagues wrote. \u201c… Obesity promotes a chronic, low-grade inflammatory state through adipokine release and up-regulation of cytokines such as tumor necrosis factor (TNF), interleukin-17 (IL-17), and IL-6, while mechanical stress at entheseal sites and reduced physical activity exacerbate musculoskeletal symptoms. <\/p>\n\n\nData derived from Merola JF, et al. Arthritis Care Res<\/i>. 2026;doi:10.1002\/art.70134. \u201cGiven the interplay between obesity, systemic inflammation, and PsA disease activity, use of an IL-17A inhibitor with an effective weight loss therapy may offer additive clinical benefits,\u201d they added.<\/p>\n
In the TOGETHER-PsA trial, Merola and colleagues assessed the efficacy and safety of combination therapy with ixekizumab (Taltz, Eli Lilly) plus tirzepatide (Mounjaro, Zepbound; Eli Lilly), compared with ixekizumab alone in a cohort of 271 adults with active PsA and overweight or obesity. Eligibility criteria included at least one comorbidity associated with overweight or obesity.<\/p>\n
A 50% improvement in ACR50 response, along with a weight reduction of 10% or greater at 36 weeks served as the primary outcome measure. Other endpoints included ACR50 alone and patient-reported outcomes. The final analysis included 138 participants in the combination therapy group and 133 in the ixekizumab alone group.<\/p>\n
According to the researchers, the primary endpoint was met by 31.7% of participants in the ixekizumab plus tirzepatide arm, compared with 0.8% of those in the monotherapy arm (P<\/i> < .001). Similarly, 33.5% of participants in the combination arm achieved ACR50, compared with 20.4% of those who received ixekizumab alone (P<\/i> = .02). Significant early separation between the two groups was observed at week 4 (nominal P<\/i> < .05), according to the findings.<\/p>\n
Nominally significant improvements were also observed in the combination arm vs. the monotherapy arm for ACR20 response (P<\/i><.001), minimal disease activity (P<\/i>< .05), and absolute Psoriasis Area and Severity Index score (P<\/i><.01). Regarding patient-reported outcomes, ixekizumab plus tirzepatide bested ixekizumab alone as assessed by Health Assessment Questionnaire-Disability Index ( = 0.2; nominal P<\/i><.001) and Functional Assessment of Chronic Illness Therapy-Fatigue (improvement of 3.8; nominal P<\/i><.01). <\/p>\n
No new safety findings were observed for either medication, according to the researchers.<\/p>\n
\u201cThis is the first randomized controlled trial of [tirzepatide] and [ixekizumab] in patients with PsA and overweight or obesity that addresses the comprehensive management needs of this patient population, with a positive meaningful impact in multiple domains of PsA disease, including disease control and its comorbidities,\u201d Merola and colleagues wrote. \u201cThese data strengthen the EULAR and GRAPPA treatment guidelines, which recommend that clinicians consider comorbidities in the patient’s treatment approach to achieve low disease activity or remission.\u201d<\/p>\n
\n
\n
Published by:<\/span>\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n \nMerola JF, et al. Arth<\/i>ritis<\/i> Care Res.<\/i> 2026;doi:10.1002\/art.70134.\n<\/p>\n\n
\n Disclosures: <\/strong>\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n Clinical Guidance, Healio CME, FDA news<\/li>\n Healio’s exclusive daily news coverage of clinical data<\/li>\n<\/ul>\nLearn more<\/button>\n<\/div>\n<\/div>\n
![\"healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/rheum.svg?la=en&h=44&w=141&hash=EBAD778B57889935130139D3FF110538\")
\n<\/div>\n<\/div>\n<\/div>\n